trial

Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

NCTId NCT01066403
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 28 (actual)
Sponsored by Heidelberg University
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2003-10
Primary completion
2008-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pergolide

Sponsors

Heidelberg UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Daniela Roesch - Ely, MDPrincipal Investigator

Sites

4 total
Mannheim, GermanyHeidelberg, GermanyHamburg, GermanyKarlsbad, Germany

Facts & assertions

4 sourced
Enrollment
28
Phase
NA
Primary Completion Date
2008-03
Status
COMPLETED
relationships
The graph out of here
drug
Pergolide
drug
lead_sponsor
Heidelberg University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Depression
indication
Schizophrenia
indication
investigator
Daniela Roesch - Ely, MD
person